Abstract DRAK2 is a serine/threonine kinase that has previously been shown to negatively regulate activation of T cells through the T cell receptor. Additionally, T cells lacking Drak2 are hypersensitive to low levels of stimulation, but are resistant to T cell mediated autoimmunity. Furthermore, Drak2-/- mice have no defects in viral immunity, making DRAK2 a novel target to replace current non-specific immunosuppressants used following transplantation. We hypothesized that Drak2 deficient T cells die after activation, and tested the ability of these T cells to respond to allogeneic stimulation. Using in vitro mixed lymphocyte reactions, Drak2-/- CD8+ T cells exhibited defects in accumulation after 5 days of allostimulation compared to wildtype T cells in vitro. Additionally, in vivo, allogeneic tumors grew uncontrolled by Drak2-/- T cells, and allogeneic skin graft rejection was significantly delayed. Overexpression of anti-apoptotic Bcl-xL in Drak2-/- T cells restored rejection of allogeneic tumors. Additionally, Drak2-/- mice had increased proportions of Tregs, and depletion of Tregs in a skin transplant model significantly enhanced Drak2-/- alloresponses. As a consequence of deletional tolerance, allogeneic memory was drastically reduced post transplant in Drak2-/- mice. Overall, these results demonstrate that DRAK2 plays a significant role in allograft responsiveness and highlight this kinase as a potential pharmacologic target in efforts to block allograft rejection.
Read full abstract